Clinical Trials on HR+HER2- Advanced Breast Cancer in Canada
Total 981 results
-
Novartis PharmaceuticalsCompletedHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerCanada
-
Jazz PharmaceuticalsActive, not recruitingHER2+/HR+ Breast CancerUnited States, Spain, Canada
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)United States, Belgium, Canada, Italy, Spain, United Kingdom
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
-
University Health Network, TorontoRecruitingBreast Cancer | HER2-positive Breast CancerCanada
-
PrecirixTerminatedAdvanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care TreatmentUnited States, Canada
-
Eli Lilly and CompanyActive, not recruitingPancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)Belgium, Spain, Korea, Republic of, United States, Taiwan, France, Canada
-
Sunnybrook Health Sciences CentreSeagen Inc.; Biocon BiologicsRecruitingHER2-positive Breast Cancer | LMDCanada
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Seagen Inc.CompletedHER2 Positive Breast CancersUnited States, Canada
-
University Health Network, TorontoActive, not recruitingBreast Cancer | Advanced Solid CancersCanada
-
Ontario Clinical Oncology Group (OCOG)Juravinski Cancer Centre FoundationCompleted
-
Sunnybrook Health Sciences CentreCompletedLocally Advanced Breast CancerCanada
-
SOLTI Breast Cancer Research GroupRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast CancerSpain
-
NSABP Foundation IncEisai Inc.CompletedBreast Cancer | HER2-negative Breast CancerUnited States, Canada
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
University Health Network, TorontoCompletedBreast Cancer | Locally Advanced Breast CancerCanada
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Lawson Health Research InstituteRecruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Ontario Clinical Oncology Group (OCOG)Completed
-
AstraZenecaNot yet recruiting
-
Novartis PharmaceuticalsCompletedSquamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer | HER2 + Gastric CancerTaiwan, Spain, Canada, Korea, Republic of, United States
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
Merrimack PharmaceuticalsCompletedHer2 Negative Breast Cancer PatientsUnited States, Spain, Canada, Germany, Russian Federation
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Merrimack PharmaceuticalsTerminatedBreast Cancer | HER2 Positive Breast CancerSpain, United States, Italy, France, Canada, Belgium, Austria, Germany, Czech Republic
-
Neovii BiotechFresenius Biotech North AmericaTerminatedAdvanced Breast Cancer | Metastatic Breast CancerUnited States, Canada
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
MedSIRHoffmann-La RocheCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerSpain, France, United Kingdom, Germany, Italy
-
Sunnybrook Health Sciences CentreHarvard UniversityUnknownBreast Neoplasm | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Brain MetastasesCanada
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingMetastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerAustria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Puma Biotechnology, Inc.CompletedHER2+ Metastatic Breast Cancer (MBC)United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Hoffmann-La RocheCompletedHER2-Positive Early Breast CancerUnited States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer; HER2-positive; MetastaticUnited States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
University Health Network, TorontoRecruitingAdvanced Breast Cancer | Advanced Colorectal Cancer | Cancer RehabilitationCanada
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingUnresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast CarcinomaUnited States, Canada
-
Spanish Breast Cancer Research GroupPierre Fabre Laboratories; Puma Biotechnology, Inc.RecruitingHER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast CancerSpain
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
MedSIRMenarini GroupRecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast CancerSpain
-
Seagen Inc.CompletedHER2 Positive Breast CancerUnited States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerBelgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia